






























Comorbid Depression Among Untreated Illicit Opiate
Users: Results From a Multisite Canadian Study
T Cameron Wild, PhD
1
, Nady el-Guebaly, MD
2
, Benedickt Fischer, PhD
3





, Julie Bruneau, MD
6
, Lina Noël, MA
7
, Jürgen Rehm, PhD
8
,
Mark Tyndall, MD, ScD
9
, Phil Mun, PhD
10
512
 Can J Psychiatry, Vol 50, No 9, August 2005
Objectives: This study aimed to describe patterns of major depression (MDD) in a cohort
of untreated illicit opiate users recruited from 5 Canadian urban centres, identify
sociodemographic characteristics of opiate users that predict MDD, and determine whether
opiate users suffering from depression exhibit different drug use patterns than do
participants without depression.
Method: Baseline data were collected from 679 untreated opiate users in Vancouver,
Edmonton, Toronto, Montreal, and Quebec City. Using the Composite International
Diagnostic Interview Short Form for Major Depression, we assessed sociodemographics,
drug use, health status, health service use, and depression. We examined depression rates
across study sites; logistic regression analyses predicted MDD from demographic
information and city. Chi-square analyses were used to compare injection drug use and
cocaine or crack use among participants with and without depression.
Results: Almost one-half (49.3%) of the sample met the cut-off score for MDD. Being
female, white, and living outside Vancouver independently predicted MDD. Opiate users
suffering from depression were more likely than users without depression to share injection
equipment and paraphernalia and were also more likely to use cocaine (Ps < 0.05).
Conclusions: Comorbid depression is common among untreated opiate users across
Canada; targeted interventions are needed for this population.
(Can J Psychiatry 2005;50:512–518)
Information on funding and support and author affiliations appears at the end of the article.
Clinical Implications
 The regional variation in rates of depression across study sites suggests that targeted
interventions may be required to ameliorate local comorbidities within the opiate-using
population.
 Needle-sharing behaviour among opiate users with depression requires systematic
investigation as a topic in its own right.
 High levels of cocaine use among the opiate users recruited for this study imply that polydrug
use is common among this population.
Limitations
 The study presented only cross-sectional relations; this precludes understanding the temporal
relations between opiate use and comorbid depression.
 Given the high representation of nonwhite participants in the study sample, use of the
CIDI-SFMD might have introduced cultural biases into our estimates of comorbidity in the
target population.
 Generalizability of the findings is unknown, owing to possible sampling and selection biases.
Key Words: depression, opiate use, risk behaviour,
injection drug use
Over the past 20 years, community studies have consis-tently established high rates of concurrent psychiatric
and substance use disorders in the general population. These
large-scale epidemiologic projects include the seminal ECA
study conducted in the US in the early 1980s (1), the NCS con-
ducted in the US during the 1990s (2), and several others coor-
dinated by the WHO ICPE (3) and the WHO World Mental
Health 2000 initiative (4). One of the primary ECA results—
that people with substance use disorders exhibit significantly
higher rates of one or more psychiatric disorders, compared
with individuals without substance use disorders—has  been
replicated in virtually all subsequent community studies, both
outside Canada (5–9) and within Canada (10,11).
With regard to diagnosis, affective disorders are prevalent
among drug users in the general population. The ECA study
found that 8% of the general US population had an affective
disorder at some time in their lifetime. However, affective dis-
orders were 4.7 times more likely among those who had
abused drugs (excluding alcohol), compared with the general
population. Among people who had abused opiates in their
lifetime, 31% had an affective disorder at some time during
their life (1). Kessler and others reported a similar
cooccurrence of lifetime prevalence of drug abuse and affec-
tive disorders (28%) but also demonstrated that 39% of people
who have been drug-dependent at some time have also had an
affective disorder (2).
Treated drug-dependent individuals in general, and treated
opiate users in particular, are more likely to experience affec-
tive disorders or depression, compared with untreated drug
users in the community. For example, 42% of people seeking
treatment for polysubstance dependence report lifetime expe-
rience with an affective disorder, and almost 19% report a life-
time history of depression (12). Other research has shown that
24% of people in drug treatment had lifetime MDD (13) and
that lifetime experience with MDD among individuals seek-
ing treatment for opiate addiction or involved with the law
ranges from 16% to 54% (14–18). Women in drug treatment
are more likely to have a diagnosis of MDD, compared with
men (13,14). Opiate users not in treatment have been shown to
have depression rates ranging between 14% and 37% (16,19).
Research to date does not allow a definitive conclusion about
whether depression precedes or follows substance depend-
ence (20,21). This is because depression can be attributed to
drug effects, drug withdrawal, or preexisting pathology or life
events (21). However, it is clear that cooccurring depression
among illicit drug users does have important behavioural and
treatment implications; for example, depression is positively
correlated with continued drug use during and after treatment
for opiate abuse (22–24). Conversely, longitudinal studies
among injection drug users and individuals with opiate addic-
tion have shown that stopping drug use leads to reduced
depressive symptoms (19,20). Moreover, depressive symp-
toms have been significantly associated with needle-sharing
behaviour among community injection drug users (25,26):
Mandell and others reported that individuals with depression
had 1.66 higher odds of needle-sharing behaviour than did
injection drug users suffering from less severe depres-
sion (26). As well, emerging evidence suggests that sequential
or concurrent use of cocaine among opiate users is associated
with increased health and economic risks and also with poorer
treatment prognosis (27).
The Present Study
Only 3 studies to date have examined comorbid depression
among untreated opiate users recruited from the community,
and all have been conducted in the US (16,19,26). Conse-
quently, relatively little is known about relations between
untreated opiate abuse and depression in the Canadian con-
text. Moreover, it is unknown whether, in Canada, opiate
users with and without depression exhibit different patterns of
injection drug use and (or) cocaine and crack cocaine use. To
address these issues, our study aimed to describe drug use and
comorbid depression in a large community sample of
untreated Canadian opiate users. The study objectives were to
describe the prevalence and distribution of MDD among
out-of-treatment opiate abusers recruited from 5 Canadian
urban centres, to identify sociodemographic characteristics of
opiate users that were associated with MDD, and to determine
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Abbreviations used in this article
CI confidence interval
CIDI-SFMD Composite International Diagnostic Interview
Short Form for Major Depression
CIHR Canadian Institutes of Health Research
ECA Epidemiologic Catchment Area
HBV hepatitis B virus
HCV hepatitis C virus
ICPE WHO International Consortium in
Psychiatric Epidemiology
IHRT Interdisciplinary Health Research Team
IV intravenous
MDD major depressive disorder
NCS National Comorbidity Survey
OPICAN multisite cohort of illicit opioid users in
5 Canadian cities
OR odds ratio
REB research ethics board
SD standard deviation
SE standard error
whether opiate users with depression exhibit different drug
use and risk-behaviour patterns than do opiate users without
depression.
Method
Study Sites and Sample
The multisite cohort of illicit opioid users in 5 Canadian cities
(OPICAN), from which data are reported here, is a research
component of a CIHR-funded IHRT investigating illicit opi-
ate addiction, research, treatment, and policy. The study pro-
tocol received ethical review board approval at all 5 study
sites via local institutional REBs. Between March and
December 2002, baseline participants were recruited by
snowball sampling and outreach methods. Snowball sampling
is a methodological approach to convenience sampling
wherein eligible participants nominate social network mem-
bers who are likely to meet study inclusion criteria (28); it is
often used to sample hard-to-reach populations such as illicit
opiate users. The OPICAN cohort was drawn from 5 cities:
Vancouver, Edmonton, Toronto, Montreal, and Quebec.
Potential participants were aged 18 years or older, were fluent
English speakers, had used opiates for a minimum of 5 of 7
days in the week preceding recruitment, had not received
treatment in the 6 months preceding recruitment (the study
protocol defined “treatment” as residential treatment, outpa-
tient treatment, all forms of opiate pharmacotherapy, and [or]
long-term residential detoxification followed by treatment),
and were currently residing in 1 of the 5 study sites. Partici-
pants who met these inclusion criteria were given a saliva test
for opioid use (AVITAR ORALscreen 4©, Avitar Technolo-
gies, Canton, MA) to biologically verify self-reported opiate
use. Compared with a urine screen, this test provides accept-
able sensitivity and specificity (29). Participants were
excluded if they were currently experiencing psychological
distress at the time of recruitment (for example, an acute psy-
chotic episode) or if they were intoxicated at the time of
recruitment. Although the study protocol did not systemati-
cally record the number of potential participants excluded by
these criteria, all participants who contacted the researchers
(whether excluded or included) received referral information
to help them access local psychiatric and addiction services.
The study cohort comprised 679 biologically verified regular
opiate users (that is, individuals, both injectors and
noninjectors, who reported using opiates on most days in the
week preceding recruitment) who were not receiving treat-
ment at the time of recruitment.
Procedure and Measures
A standardized baseline protocol was administered in a
one-on-one interview conducted with all participants. It
included written and oral informed consent; social, health,
and drug use items; a psychiatric assessment; and a saliva
immunoassay screen for infectious disease (specifically, HIV,
HCV, and HBV). Assessments were conducted anonymously
(via anonymous study code), and all participant data were and
are treated confidentially. Participants received $20 for base-
line assessment and are being followed over a 3-year period.
Because the study is collecting final follow-up data, follow-up
rates are not currently available. This paper only reports base-
line results for the OPICAN cohort. The psychiatric assess-
ment included the CIDI-SFMD, a brief version of the full
CIDI interview that has been used to indicate MDD in survey
research (30–33).
Results
Characteristics of the Sample and Patterns of Depression
Table 1 presents the sample’s sociodemographic characteris-
tics. Values for the CIDI-SFMD were missing for 6 partici-
pants, and values for the other demographic variables were
missing for 13 participants, yielding 657 participants with
complete data for analyses. Among these 657 participants,
66.5% were men, 68.2% were white, 16.3% were Aboriginal,
and 49.3% met the CIDI-SFMD cut-off score for inferring
MDD. The average age of the sample was 34.7 years. Analy-
ses indicated that, compared with the overall sample, fewer
participants recruited from the Vancouver site met the cut-off
for MDD (34.2%, compared with 49.3%; P < 0.05) and that
more participants recruited from the Montreal site met the
cut-off score for MDD (58.7%, compared with 49.3%;
P < 0.05).
Socioeconomic Predictors of MDD
Table 2 presents results of logistic regression analyses pre-
dicting the presence or absence of MDD from sex, ethnicity,
recruitment site, and housing status. In each analysis, predic-
tor variables were forced into the regression equation as a sin-
gle set. We conducted 2 analyses: one used unweighted data,
and the other took into account variations in sample size at
each study site by weighting these data by the number of sub-
jects for each city. The weighted analysis indicated that
depression was more common among women, relative to men
(OR 1.70; 95%CI, 1.19 to 2.42; P < 0.05); among white partic-
ipants, relative to nonwhite participants (OR 1.51; 95%CI,
1.02 to 2.23; P < 0.05); and among OPICAN participants liv-
ing in Edmonton, Toronto, Montreal, and Quebec City, rela-
tive to those in Vancouver (ORs 2.10, 2.18, 2.23, and 2.27,
respectively; 95%CIs, 1.24 to 4.03, respectively; Ps < 0.05).
Living in stable housing, compared with transitional housing
or with living on the street, was not associated with depres-
sion. Exploratory logistic regression analyses indicated no
significant interactions between city of recruitment and sex,
ethnicity, or housing status in the prediction of MDD.
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Injection Drug Use and Cocaine Use
Table 3 presents results of chi-square analyses comparing
injection drug use patterns among participants with and with-
out depression. Although more than 93% of study participants
in each subsample reported using needles to inject opiates at
some time in their lives, participants with depression reported
sharing needles and injection paraphernalia more often in the
30 days preceding the interview (29.6%), compared with par-
ticipants without depression (20.4%, P < 0.05). In addition,
participants with depression were more likely to have
reported experiencing a drug overdose in the 6 months pre-
ceding study recruitment (21.0%), compared with partici-
pants without depression (13.6%, P < 0.05).
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Men, % 56.3* (3.6) 67.8 (5.0) 74.2* (3.5) 69.0 (5.0) 69.6 (3.9) 66.5 (1.8)
Mean age, years 34.6 (9.0) 39.1 (6.9) 29.0** (9.3) 35.1 (8.9) 38.5 (8.7) 34.7 (9.4)
Ethnicity, %
White 40.0* (3.6) 54.0* (5.4) 88.4* (2.6) 95.4 (2.3) 76.1* (3.6) 68.2 (1.8)
Aboriginal 34.2* (3.5) 32.2* (5.1) 1.3* (0.9) 3.4* (2.0) 6.5* (2.1) 16.3 (1.4)
Other 25.8* (3.2) 13.8 (3.7) 10.3* (2.5) 1.1* (1.1) 17.4 (3.2) 15.5 (1.4)
With depression, % 34.2* (3.5) 50.6 (5.4) 58.7* (4.0) 58.6 (5.3) 52.9 (4.3) 49.3 (2.0)
CIDI-SFMD, mean score 1.95** (2.7) 2.76 (2.9) 3.19 (2.8) 2.9 (2.9) 3.0 (3.0) 2.7 (2.9)
a
Data in parentheses are SEs for proportions and SDs continuous variables.
*Significant at P < 0.05 with adjusted standardized residual > 2.0
**When variances were unequal, statistical significance is based on nonparametric Kruskal–Wallis tests ( P < 0.05). Vancouver had significantly
lower CIDI-SFMD scores than other sites (mean rank = 278.2, 
2
= 18.03, P = 0.001); Montreal participants were significantly younger than those
from other sites.
(mean rank = 211.7, 
2
= 100.04, P < 0.001)
Table 2 Variables associated with depression among untreated illicit opiate users: unweighted and





Adjusted OR (95% CI)
Analysis weighted by recruitment site
Sex
Men 437 Reference Reference
Women 220 1.68 (1.18 to 2.39)* 1.70 (1.19 to 2.42)*
Age 0.98 (0.96 to 1.00) 0.98 (0.97 to 1.00)
Ethnicity
Nonwhite 209 Reference Reference
White 448 1.42 (0.97 to 2.08) 1.51 (1.02 to 2.23)*
Site
Vancouver 190 Reference Reference
Edmonton 87 2.10 (1.22 to 3.61)* 2.10 (1.24 to 3.55)*
Montreal 155 2.23 (1.35 to 3.70)* 2.24 (1.28 to 3.91)*
Quebec City 87 2.27 (1.25 to 4.11)* 2.27 (1.28 to 4.03)*
Toronto 138 2.18 (1.34 to 3.55)* 2.14 (1.26 to 3.65)*
Stable housing 302 1.23 (0.88 to 1.72) 1.15 (0.83 to 1.61)
*P < 0.05
Table 4 presents the results of chi-square analyses comparing
different patterns of cocaine and (or) crack cocaine use among
participants with and without depression. A high proportion
of study participants in each subsample reported combining
and (or) switching between opiates and other drug types; how-
ever, this was not related to depression. Instead, participants
suffering from depression generally reported using cocaine
more frequently (30.6%) than did participants without depres-
sion (23.7%, P < 0.05). Conversely, participants with depres-
sion reported smoking crack cocaine less frequently (18.2%)
than did participants without depression (33.9%, P < 0.05).
Discussion
To our knowledge, this is the first study to document
comorbid depression among untreated illicit opiate users in
Canada. Across 5 urban centres, almost one-half of the
recruited opiate users met CIDI-SFMD criteria for MDD.
This high level of comorbidity has also been reported among
untreated US samples of opiate users (16,19), although we
obtained slightly higher prevalence rates for depression in the
present study. Inconsistencies in measuring MDD across
studies may account for divergent results relative to other
research. Logistic regression analysis identified 3 independ-
ent predictors of depression: being a woman, being white, and
living outside Vancouver. A higher rate of depression among
female opiate users has also been reported in US sam-
ples (13,14), although these other results were obtained for
treated opiate users. It is unclear why greater depression was
observed among white drug users and among those living out-
side Vancouver. One explanation for the ethnicity differences
may relate to the cross-cultural applicability of the
CIDI-SFMD items in regard to Aboriginal and other nonwhite
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Table 3 Depression and injection drug use: overall sample
a
Opiate users
Variable % with depression % without depression
Used needles
Lifetime (n = 657) 93.8 (1.3) 93.4 (1.4)
Past 30 days (n = 615) 78.7 (2.3) 82.6 (2.1)
Average number of injections daily in past 30 days
Did not inject 21.3 17.4
Once daily or less 8.6 11.7
2 to 4 times daily 39.5 37.5
5+ times daily 30.6 33.3
Shared needles or injection paraphernalia in past 30 days 29.6 (2.5) 20.4 (2.2)*
Overdosed in past 6 months 21.0 13.6 (1.9)*
a
Data in parentheses are SEs for proportions.
*Significant chi-square statistic at P < 0.05; adjusted standardized residuals > 2.0
Table 4 Depression and the use of cocaine and crack cocaine
a
Opiate users
Variable % with depression % without depression
Combined opiate use with nonopiates 71.8 (2.5) 69.2 (2.5)
Cocaine and (or) crack use
Did not use cocaine or crack 22.2 15.9*
Cocaine and crack use 29.0 26.4
Cocaine use only 30.6 23.7*
Crack use only 18.2 33.9*
a
Data in parentheses are SEs for proportions.
*Significant chi-square statistic at P < 0.05; adjusted standardized residuals > 2.0
populations. Further research is required to examine this
issue, given the diverse ethnic background in our sample of
untreated opiate users.
The present results also replicate US findings indicating that
opiate users suffering from depression may be particularly
likely to engage in unsafe drug use patterns (24,25) Specifi-
cally, we observed that opiate users with depression shared
needles and injection paraphernalia more frequently, com-
pared with those not suffering from depression. Although the
mechanism underlying this effect is unclear, several plausible
lines of investigation may prove fruitful. For example,
Mandell and others reported that IV drug users with severe
depression who also had large drug-using social networks
exhibited 2.59 times higher odds to engage in needle-sharing
behaviour, compared with IV drug users exhibiting low
depression levels (26). Further research is required to deter-
mine whether social network dynamics also exhibit synergis-
tic effects on risky injection practices among opiate users with
depression in Canadian cities. It may also be helpful to under-
take more in-depth investigation of opiate users’ attitudes
toward infectious disease transmission risks, as well as tactics
they use to cope with stressful life events, in the context of
understanding the relation between depression and opiate use.
Compared with users not suffering from depression, opiate
users with depression were more likely to use cocaine but less
likely to smoke crack cocaine. Other research on patterns of
opioid and cocaine use in the OPICAN cohort suggests that
switching between opioid and cocaine use does not reflect
independent drug habits but, rather, reflects attempts to
achieve contrasting drug effects by using substances with dif-
ferent psychopharmacological profiles (34).
Generalizability of the present findings is limited for several
reasons. First, this study used snowball and opportunistic
sampling procedures. Consequently, it is not known whether
the sample accurately represents the entire population of
untreated opiate users in Canada. In addition, selection bias
was probably present in the sample, given that participants
had, first, to be known and (or) available to outreach staff in
each study site and, second, to be interested in participating in
a 3-year cohort study. Additional research is therefore
required to replicate the present findings in community sur-
veys and other studies of Canadian opiate users who have not
sought treatment. Finally, given that some Canadian research
using the CIDI-SFMD suggests that the brief instrument may
overestimate rates of depression in community samples (33),
replication of the study is required, ideally with a standardized
protocol that administers several indicators of MDD.
Despite these limitations, this is the first large Canadian study
across 5 major urban centres to suggest that MDD is a signifi-
cant psychiatric concern among untreated opiate users.
Because opiate users experiencing MDD do respond to com-
bined pharmacotherapy and psychotherapy (21,24), it is
essential to develop innovative outreach and comorbidity
treatment programs to reduce the population burden of
comorbid depression in the context of opiate abuse.
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Résumé : La dépression comorbide chez les utilisateurs d’opiacés illicites non
traités : résultats d’une étude multisite canadienne
Objectifs : Cette étude visait 1) à décrire les modèles de dépression majeure (TDM) dans une cohorte
d’utilisateurs d’opiacés illicites non traités, recrutés dans 5 centres urbains du Canada, 2) à identifier
les caractéristiques sociodémographiques des utilisateurs d’opiacés qui prédisent le TDM, et 3) à
déterminer si les utilisateurs d’opiacés souffrant de dépression révèlent des modèles d’utilisation de
drogues différents de ceux des participants sans dépression.
Méthode : Les données de départ ont été recueillies auprès de 679 utilisateurs d’opiacés non traités à
Vancouver, Edmonton, Toronto, Montréal et Québec. Nous avons évalué les données
sociodémographiques, l’utilisation de drogues, l’état de santé, l’utilisation des services de santé et la
dépression, à l’aide de la version abrégée de l’entrevue diagnostique composite internationale pour la
dépression majeure. Nous avons examiné les taux de dépression entre les sites de l’étude; des
analyses de régression logistique ont prédit le TDM d’après les données démographiques et la ville.
Des analyses du chi-carré ont servi à comparer les participants avec et sans dépression, en ce qui
concerne l’utilisation de drogues injectables, de cocaïne et de crack.
Résultats : Presque la moitié (49,3 %) de l’échantillon atteignait le score du seuil d’inclusion du
TDM. Être femme, blanc et vivre à l’extérieur de Vancouver prédisait indépendamment le TDM. Les
utilisateurs d’opiacés souffrant de dépression étaient plus susceptibles que les utilisateurs sans
dépression de partager du matériel de drogues injectables et des accessoires, et étaient aussi plus
susceptibles d’utiliser de la cocaïne (P < 0,05).
Conclusions : La dépression comorbide est répandue chez les utilisateurs d’opiacés non traités au
Canada; des interventions ciblées sont nécessaires pour cette population.
